Core Viewpoint - BioVersys AG announced promising Phase 2a clinical trial results for AlpE, a novel antibacterial product aimed at treating pulmonary tuberculosis (TB), published in the New England Journal of Medicine, highlighting its potential to address multidrug-resistant (MDR) TB [1][7]. Company Overview - BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious infections caused by MDR bacteria, with its most advanced programs targeting nosocomial infections and tuberculosis [14]. Clinical Trial Details - The Phase 2a bEto-TB clinical trial, conducted in South Africa, demonstrated AlpE's early bactericidal activity in patients with pulmonary TB, suggesting it could replace isoniazid in current treatment regimens or be added to future therapies [3][5]. - The trial was completed in April 2024 and involved a collaboration with TASK, GSK, and BioVersys [3]. Drug Mechanism and Collaboration - Alpibectir (AlpE) operates through a novel mechanism that enhances the efficacy of the existing antibiotic ethionamide, identified through a collaboration with GSK and academic institutions [2][5]. - The development of AlpE has been supported by various European Union grants and public-private partnerships, including the EU Innovative Medicines Initiative [4]. Industry Context - Tuberculosis remains a leading cause of death from infectious diseases globally, with increasing drug resistance complicating treatment efforts. In 2024, an estimated 10.7 million people developed TB, with approximately 1.23 million fatalities [9][10]. - The burden of TB is concentrated in 30 high-burden countries, with India, Indonesia, and the Philippines among the top contributors to global TB cases [11].

Core Viewpoint - The company ICG plc has announced a share buyback program of up to 15,280,825 ordinary shares, representing approximately 5.26% of its issued share capital, to facilitate the issuance of non-voting shares to Amundi as part of a strategic partnership [2][3][4]. Share Buyback Program - The share buyback aims to reduce the issued ordinary share capital and will be executed in tranches, with repurchased shares held as treasury shares before eventual cancellation [4][6]. - The total consideration for the repurchased ordinary shares will not exceed £316 million, and the program will commence on 26 February 2026 and expire on 30 June 2027, unless the 2025 Authority expires without renewal [7][8]. - The buyback will be conducted on the London Stock Exchange and will adhere to market regulations, with a maximum price set at 105% of the average market quotations for the five business days preceding the purchase [9][10]. Non-Voting Shares - The non-voting shares will have the same nominal value and economic rights as ordinary shares but will not carry voting rights. They will convert into ordinary shares upon a valid transfer under specific conditions [5][3]. - Amundi will reimburse ICG for reasonable costs associated with the share buyback, and the subscription price for the non-voting shares will match the price paid for the repurchased ordinary shares [3][4]. Appointment of Non-Executive Director - Vincent Mortier has been appointed as a Non-Executive Director, effective from 31 March 2026, as part of the strategic partnership with Amundi. He will also serve on the Nominations and Governance Committee [11][12]. - Mortier brings extensive experience from his roles at Amundi and Societe Generale, which is expected to enhance the expertise of ICG's Board [12][13].

Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-energy Cyclone® KIUBE 300 cyclotrons. The ...

OSLO, NORWAY (19 February 2026) – The shares in TGS ASA will be traded ex dividend NOK 1.47 (USD 0.155) as from today, 19 February 2026. ...

Press releaseFebruary 19, 2026 Renault Group demonstrates its resilience, the robustness of its strategy, and moves forward with confidence Renault Group achieved strong profitability and cash generation, delivering on its 2025 financial outlook, updated on July 15, 2025: Group revenue: €57.9 billion, +3.0% and +4.5% at constant exchange rates1 vs. 2024. This robust performance was driven by its complementary auto brands, all three of them delivering growth supported by the International Game Plan roll-out ...

Amy Flikerski steps down from the Elis Supervisory Board Puteaux, 19 February 2026 – Amy Flikerski, a member of the Supervisory Board of Elis since June 2020, originally proposed by CPP Investments, has informed Elis that she was resigning from her duties of the Supervisory Board of Elis, effective February 18, 2026. In this role, she also served on the Corporate Social Responsibility Committee. This decision follows the sale of 7,027,199 Elis shares announced on February 12, 2026, and is in accordance with ...

Core Insights - Nexans reported strong financial performance for FY 2025, with adjusted EBITDA of €728 million, up 27.3% year-on-year, and a net income of €358 million, reflecting a 26.6% increase from 2024 [3][12][7] - The company achieved an exceptional organic growth rate of 8.3% in 2025, significantly exceeding mid-term guidance, driven by strong performance in the PWR-Transmission segment [2][4][8] - Nexans is focusing on electrification and has entered exclusive negotiations for the sale of its Autoelectric business, marking the completion of its portfolio rotation [4][34][35] Financial Performance - Standard sales reached €6.1 billion in 2025, with current sales at €7.8 billion, reflecting a 12.9% increase [7][8] - Adjusted EBITDA margin improved to 11.9%, up 161 basis points from 2024, indicating enhanced operational efficiency [3][11] - Free cash flow was reported at €344 million, a significant increase of 94.1% compared to €177 million in 2024, showcasing strong cash generation capabilities [13][7] Segment Performance - PWR-Transmission segment achieved standard sales of €1.7 billion, with an organic growth of 29.8%, driven by high installation activity [20][21] - PWR-Grid segment reported standard sales of €1.3 billion, with organic growth of 5.5%, supported by strong underlying trends [24][25] - PWR-Connect segment saw standard sales of €2.3 billion, with a 3.6% organic growth, bolstered by acquisitions and strong demand in the Americas and Middle East [27][28] M&A Activity - Nexans completed acquisitions of Cables RCT in Spain and Electro Cables in Canada, enhancing its portfolio and market presence [5][32][33] - The company is actively pursuing M&A as a core strategy for growth, supported by a solid balance sheet and cash generation [5][31] Sustainability Initiatives - Nexans achieved a recycled copper content of 19.3%, moving towards a target of 25% by 2028, reflecting its commitment to sustainability [39][40] - The company reported a 49% reduction in Scope 1 and 2 emissions and a 40% reduction in Scope 3 emissions, exceeding interim decarbonization targets [42][41] 2026 Outlook - For FY 2026, Nexans expects adjusted EBITDA between €730 million and €810 million, with free cash flow projected between €210 million and €310 million [2][46] - The company anticipates a softer first half of 2026 compared to the second half, excluding contributions from ongoing projects and acquisitions [2][46]

Core Insights - Harju Elekter achieved strong financial results in 2025, with revenue reaching 174.0 million euros, consistent with the previous year, and a significant increase in profitability, including a record operating profit of 12 million euros and net profit exceeding 10 million euros [4][6][22]. Revenue and Financial Results - In Q4 2025, revenue increased by 58.6% year-on-year, reaching 47.5 million euros, while annual revenue remained stable at 174.0 million euros, a slight decrease of 0.4% from 2024 [6][22]. - Gross profit for Q4 2025 was 5.3 million euros, nearly tripling from 1.8 million euros in Q4 2024, with an operating profit of 1.8 million euros compared to a loss of 1.7 million euros in the previous year [8][22]. - The company reported a net profit of 2.6 million euros in Q4 2025, a significant turnaround from a loss of 2.3 million euros in Q4 2024, with earnings per share increasing to 0.14 euros [9][22]. Market Performance - The Estonian market showed strong growth, with Q4 revenue of 9.2 million euros, a 73.0% increase year-on-year, and full-year revenue rising to 29.9 million euros [12]. - Norway experienced the most substantial growth in Q4, with revenue tripling to 11.1 million euros and a full-year increase of 49.1%, totaling 39.3 million euros [14]. - Finland remained the largest market despite a decline in full-year revenue to 54.7 million euros, attributed to lower sales volumes in project-based contracts [13]. Strategic Focus and Investments - The company focused on improving profitability through selective project management and enhancing operational efficiency, which contributed to the growth in profitability [2]. - Total investments during the reporting period amounted to 5.1 million euros, aimed at improving production efficiency and developing new products, including a new-generation electric vehicle charger [16][18]. Shareholder Returns - The Management Board proposed a dividend payment of 0.25 euros per share, reflecting the strong financial performance and increased order book [5].

Core Insights - Rapid Nutrition PLC is transitioning to a personalized, platform-led HealthTech model focused on evidence-based nutrition and immune wellness, supported by long-term institutional funding and a well-capitalized position for execution [2][6] Company Strategy - The company operates a portfolio of science-led wellness brands, including SystemLS® for evidence-based nutrition and Azurene™ for immune wellness, with ongoing product refinement and expansion in the APAC region [3][4] - Rapid Nutrition is expanding its product portfolio through licensed, evidence-based ingredients in high-demand functional nutrition categories [4] Business Model - The company employs a diversified, multi-channel business model that includes direct-to-consumer, subscription, wholesale, practitioner, and strategic partnership channels [5] - Discussions are underway with a target group that aligns with the company's strategic criteria, indicating confidence in progressing opportunities in the near term [5] Growth Priorities - The company aims to enhance personalized assessment frameworks, accelerate product-led growth in priority evidence-based categories, optimize direct-to-consumer and marketplace channels, and pursue targeted international expansion across APAC and the United States [9]

Core Insights - Fortuna Mining Corp. reported record free cash flow of $132.3 million for Q4 2025 and $330.0 million for the full year, achieving its operational plan and production guidance [1][8] - The company streamlined its portfolio by divesting non-core assets and is positioned for growth at Diamba Sud and the Séguéla plant expansion, supported by a strong balance sheet with $704 million in liquidity and $381 million in net cash [2][8] Financial Performance - The company achieved sales of $270.2 million in Q4 2025, a 40% increase from $195.2 million in Q4 2024, and $947.1 million for the full year, up from $677.2 million [11][60] - Attributable net income from continuing operations was $68.1 million or $0.22 per share for Q4 2025, compared to $14.7 million or $0.05 per share in Q4 2024, reflecting a 219% increase [11][26] - Adjusted attributable net income for Q4 2025 was $71.3 million or $0.23 per share, up from $19.4 million or $0.06 per share in Q4 2024, driven by higher realized gold prices [11][27] Operational Highlights - Gold equivalent production was 65,130 ounces in Q4 2025, with total production for the year reaching 317,001 GEOs, meeting annual guidance [9][11] - Consolidated cash cost per GEO was $971 for Q4 2025, a 9% increase from $918 in Q4 2024, while all-in sustaining costs (AISC) rose to $2,054 per GEO, an 18% increase from $1,842 in Q4 2024 [11][24][25] - The total recordable injury frequency rate for the year was 0.74, indicating strong safety performance with zero lost time injuries in Q4 [9] Growth and Development - The company expanded mineral reserves at the Séguéla mine by 31%, extending the mine life to over 9 years, and commissioned a feasibility study to increase plant throughput by 15 to 40% [12] - Approximately $67 million has been allocated to advance early works at the Diamba Sud Gold Project, with a construction decision targeted for mid-2026 [12] Cash Flow and Capital Expenditures - Net cash provided by operating activities for Q4 2025 was $162.3 million, up from $99.2 million in Q4 2024, driven by higher sales and favorable changes in working capital [22][30] - Free cash flow from ongoing operations in Q4 2025 was $132.3 million, a significant increase from $51.1 million in Q4 2024, reflecting higher cash from operating activities and reduced sustaining capital expenditures [23][30]